{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:32:10Z","timestamp":1791502330863,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002842","name":"Chiang Mai University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002842","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.drugalcdep.2020.108467","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T08:59:57Z","timestamp":1608713997000},"page":"108467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6203-1206","authenticated-orcid":false,"given":"Manit","family":"Srisurapanont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surinporn","family":"Likhitsathian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6408-769X","authenticated-orcid":false,"given":"Sirijit","family":"Suttajit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narong","family":"Maneeton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6125-6489","authenticated-orcid":false,"given":"Benchalak","family":"Maneeton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awirut","family":"Oon\u2010arom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6996-9202","authenticated-orcid":false,"given":"Chawisa","family":"Suradom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2020.108467_bib0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0010","series-title":"Negative Versus Positive Schizophrenia","first-page":"28","article-title":"Positive and negative symptoms: assessment and validity","author":"Andreasen","year":"1991"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0015","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12874-019-0829-2","article-title":"BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network Meta-analyses","volume":"19","author":"B\u00e9liveau","year":"2019","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ijnp\/pyw041.293","article-title":"Efficacy and safety of aripiprazole for maintenance treatment of methamphetamine dependence following methamphetamine psychosis: a naturalistic retrospective study","volume":"19","author":"Boonlue","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0025","doi-asserted-by":"crossref","first-page":"e2710","DOI":"10.1002\/hup.2710","article-title":"Methamphetamine-associated psychosis: clinical presentation, biological basis, and treatment options","volume":"34","author":"Chiang","year":"2019","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0030","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/add.12073","article-title":"Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial","volume":"108","author":"Coffin","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A power primer","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0040","series-title":"The Handbook of Research Synthesis and Meta-Analysis","year":"2019"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3109\/00952990.2013.861843","article-title":"Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis","volume":"40","author":"Farnia","year":"2014","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0050","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3389\/fpsyt.2019.00740","article-title":"Antipsychotics for amphetamine psychosis: a systematic review","volume":"10","author":"Fluyau","year":"2019","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0055","series-title":"Methamphetamine Treatment Guidelines: Practice Guidelines for Health Professionals","author":"Grigg","year":"2019"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0060","series-title":"Statistical Methods for Meta-analysis","author":"Hedges","year":"1985"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0065","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]","author":"Higgins","year":"2011"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0070","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0075","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0080","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"Suppl 3","key":"10.1016\/j.drugalcdep.2020.108467_bib0085","first-page":"S43","article-title":"A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis","volume":"88","author":"Leelahanaj","year":"2005","journal-title":"J. Med. Assoc. Thai."},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0090","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1176\/ajp.2007.164.7.1050","article-title":"Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison","volume":"164","author":"McEvoy","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0095","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/j.1360-0443.2005.01160.x","article-title":"The nature, time course and severity of methamphetamine withdrawal","volume":"100","author":"McGregor","year":"2005","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0100","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/add.14170","article-title":"Methamphetamine psychosis: insights from the past","volume":"113","author":"McKetin","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0105","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1111\/j.1360-0443.2006.01496.x","article-title":"The prevalence of psychotic symptoms among methamphetamine users","volume":"101","author":"McKetin","year":"2006","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0110","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jamapsychiatry.2013.283","article-title":"Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study","volume":"70","author":"McKetin","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0115","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/add.12474","article-title":"Does methamphetamine use increase violent behaviour? Evidence from a prospective longitudinal study","volume":"109","author":"McKetin","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0120","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.2147\/NDT.S120374","article-title":"Blonanserin treatment in patients with methamphetamine-induced psychosis comorbid with intellectual disabilities","volume":"12","author":"Okazaki","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0125","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0130","series-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2020"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.01.040","article-title":"Treatment of toxicity from amphetamines, related derivatives, and analogues: a systematic clinical review","volume":"150","author":"Richards","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0140","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40429-015-0077-4","article-title":"Understanding the relationship between amphetamines and psychosis","volume":"2","author":"Rognli","year":"2015","journal-title":"Curr. Addict. Rep."},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0145","series-title":"RStudio: Integrated Development for R. RStudio","author":"RStudio Team","year":"2020"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0150","series-title":"Netmeta: Network Meta-analysis Using Frequentist Methods","author":"R\u00fccker","year":"2020"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0155","doi-asserted-by":"crossref","first-page":"e7988","DOI":"10.17795\/ijpbs-7988","article-title":"Methamphetamine-associated psychosis and treatment with haloperidol and risperidone: a pilot study","volume":"10","author":"Samiei","year":"2016","journal-title":"Iran. J. Psychiatry Behav. Sci."},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0160","series-title":"Meta-Analysis With R","author":"Schwarzer","year":"2015"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0165","series-title":"Treatment for Amphetamine Psychosis. Cochrane Database Syst. Rev. CD003026","author":"Shoptaw","year":"2009"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0170","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1017\/S1461145703003675","article-title":"Psychotic symptoms in methamphetamine psychotic in-patients","volume":"6","author":"Srisurapanont","year":"2003","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0175","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.pnpbp.2011.01.014","article-title":"Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysis","volume":"35","author":"Srisurapanont","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0180","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/13651501.2012.667116","article-title":"A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis","volume":"17","author":"Sulaiman","year":"2013","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0185","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/ajp.2007.164.1.160","article-title":"A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence","volume":"164","author":"Tiihonen","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0190","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1007\/s00213-014-3485-6","article-title":"Treatment of methamphetamine-induced psychosis: a double-blind randomized controlled trial comparing haloperidol and quetiapine","volume":"231","author":"Verachai","year":"2014","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0195","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jsat.2015.11.009","article-title":"Aripiprazole and risperidone for treatment of methamphetamine-associated psychosis in chinese patients","volume":"62","author":"Wang","year":"2016","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0200","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3389\/fpsyt.2020.00237","article-title":"Randomized controlled trial of Paliperidone extended release versus risperidone for the treatment of methamphetamine-associated psychosis in chinese patients","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0205","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1055\/s-0042-123752","article-title":"Evidence-based guidelines for the pharmacological management of acute methamphetamine-related disorders and toxicity","volume":"50","author":"Wodarz","year":"2017","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.drugalcdep.2020.108467_bib0210","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009786","article-title":"Olanzapine and haloperidol for the treatment of acute symptoms of mental disorders induced by amphetamine-type stimulants","volume":"97","author":"Xue","year":"2018","journal-title":"Medicine (Baltimore)"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871620306323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871620306323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T17:28:17Z","timestamp":1732296497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871620306323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":42,"alternative-id":["S0376871620306323"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108467","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108467","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108467"}}